GHK-Cu

GHK-Cu: an unapproved, investigational copper–tripeptide complex made from glycyl-L-histidyl-L-lysine bound to Cu(II), widely discussed in cosmetic and peptide markets but not established as an approved human injectable drug.

Overview

The central scientific and compliance problem with injectable GHK-Cu is evidence transfer. GHK-Cu has real biochemical plausibility as a copper-binding tripeptide with wound-healing, extracellular-matrix, and inflammatory-signaling literature behind it, but the public evidence base is dominated by chemistry papers, preclinical biology, topical/cosmetic discussion, and some veterinary or locally delivered wound-healing work rather than same-molecule human injectable PK, safety, dose-ranging, or efficacy trials. Current consumer interest has moved faster than the clinical evidence. [Copper peptide GHK-Cu encyclopedic record, 2026; Marie Claire, 2026; Allure, 2026]

For injectable development, GHK-Cu has one attractive feature and two major liabilities. The attractive feature is its strong copper chelation and small molecular size, which make local tissue delivery and high aqueous solubility plausible. The liabilities are that the copper–peptide complex is chemically sensitive to pH, competing ligands, and prolonged aqueous exposure, and there is no labeled human injectable product, route-specific human PK, or validated dosing range for IV, IM, SC, intradermal, or intralesional administration. That means almost every route-specific claim in current peptide channels is either empirical, extrapolated, or commercial rather than clinically established. [Copper peptide GHK-Cu encyclopedic record, 2026; Marie Claire, 2026]

Regulatory posture is cautionary. Public reporting in 2026 described GHK-Cu as part of a broader FDA peptide-compounding controversy and gray-market peptide ecosystem, but such discussion is not approval, dose validation, or safety clearance. More generally, FDA states that compounded drugs are not FDA-approved, and recent Reuters reporting reiterated the agency's position that compounded products do not go through the FDA approval process and are subject to specific statutory limits. [Allure, 2026; Reuters, 2026]

What it is

GHK is the tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is the Cu(II) complex of that tripeptide, commonly also discussed as copper tripeptide-1 in cosmetic nomenclature and sometimes referred to with legacy names such as prezatide copper in peptide discourse. Accessible chemical records list the free peptide as C14H24N6O4 with a molecular weight of 340.38 g/mol and the copper complex near 403 g/mol depending on representation and protonation state. [Copper peptide GHK-Cu encyclopedic record, 2026; GHK-Cu German encyclopedic record, 2026]

The chemistry matters because the peptide and the metal complex are not interchangeable. Free GHK and copper-complexed GHK-Cu do not behave identically, and the therapeutic rhetoric around "copper peptides" often blurs the copper-bound form, the free tripeptide, and cosmetic INCI naming into one idea. That slippage is especially dangerous when people move from serums or creams to sterile injections, because a parenteral drug product must control the complex stoichiometry, copper source, impurity profile, sterility, endotoxin, and solution-state stability in a way a cosmetic ingredient does not. [Copper peptide GHK-Cu encyclopedic record, 2026; Marie Claire, 2026]

The best physicochemical summary is that GHK-Cu is a small, water-soluble peptide–metal complex with strong affinity for Cu(II). The listed water solubility is around 130.98 g/L and there is a high copper-binding constant around log10 16.44 — close to albumin's high-affinity copper-binding region. At physiologic pH, the complex is described as involving the histidine imidazole nitrogen, the glycine amino nitrogen, and the deprotonated amide nitrogen, with additional coordination contributions proposed to explain the unusually high stability constant. Those details are useful for formulation science, but they are not proof of clinical performance. [Copper peptide GHK-Cu encyclopedic record, 2026; GHK-Cu French encyclopedic record, 2026]

A clear rule follows from that chemistry: evidence for topical copper tripeptide-1, scaffold-bound GHK derivatives, biotinylated GHK wound matrices, veterinary topical studies, or other copper therapeutics such as subcutaneous copper histidinate should not be collapsed into "injectable GHK-Cu." The copper ion is not the same drug just because both molecules contain copper, and route/formulation differences are load-bearing here. [Reuters, 2026; Copper histidinate record, 2026; Copper peptide GHK-Cu encyclopedic record, 2026]

How it's proposed to work

The most defensible mechanistic anchor is copper handling. GHK-Cu is a high-affinity Cu(II) chelate that appears capable of binding copper strongly enough to compete with physiologic carriers in some contexts while dampening free-copper redox activity. That makes it scientifically plausible as a copper-delivery or copper-buffering signal complex rather than just a generic peptide. The redox activity of copper is described as "silenced" when bound to GHK, which is part of why the complex is biologically interesting. [Copper peptide GHK-Cu encyclopedic record, 2026]

The second mechanistic anchor is extracellular-matrix and tissue-remodeling biology. The literature most often linked to GHK-Cu describes increased collagen and glycosaminoglycan synthesis in fibroblast-rich systems, modulation of decorin, angiogenic signaling, and wound-environment remodeling. That is the biological backbone behind the skin/scar/wound narrative. But almost all of that backbone sits in cell, rodent, rabbit, scaffold, or topical contexts. It is still a mechanistic map, not proof that a sterile injected solution safely reproduces those effects in humans at a useful therapeutic window. [Copper peptide GHK-Cu encyclopedic record, 2026; GHK-Cu French encyclopedic record, 2026]

A third mechanistic point is that GHK-Cu's local-versus-systemic logic is highly route-dependent. For topical or intradermal, the desired outcome is usually concentrated exposure in the dermis, where fibroblasts, inflammatory cells, microvascular endothelium, and ECM turnover are most relevant. For systemic IV or SC delivery, the dominant processes become protein binding, enzymatic degradation, renal filtration of unbound species, tissue redistribution of copper, and ligand exchange with endogenous carriers such as albumin and ceruloplasmin. That is a fundamentally different pharmacologic question. [Copper peptide GHK-Cu encyclopedic record, 2026; Marie Claire, 2026]

The mechanism also cuts against overclaiming. A molecule that modulates copper traffic and matrix turnover could, in principle, become helpful in one tissue context and unhelpful in another. That is why route discipline matters so much. A local dermal microdose concept and a systemic IV wellness concept are not just different delivery methods for the same claim; they are different biological experiments. [Copper peptide GHK-Cu encyclopedic record, 2026]

Common forms in circulation

No FDA-approved GHK-Cu injectable drug product was identified. Public reporting instead places GHK-Cu inside current peptide-compounding controversy and gray-market peptide use. That is a very different posture from a labeled sterile injectable with validated CMC, toxicology, and route-specific instructions. [Allure, 2026; Reuters, 2026]

Public-facing discourse currently centers on topical serums, cosmetic copper-peptide products, and a growing peptide gray market in which compounds are purchased online, often as powders or vials, and discussed in self-experimentation communities. Beauty and lifestyle coverage in 2026 repeatedly noted that injectable GHK-Cu interest is rising even though clinical data and regulation lag behind. [Marie Claire, 2026; New York Post, 2026; Business Insider, 2026]

Names and aliases

Key names include GHK, GHK-Cu, glycyl-L-histidyl-L-lysine, copper tripeptide-1, copper peptide, and prezatide copper. Confusion intensifies when GHK-Cu is stacked rhetorically with BPC-157, TB-500, KPV, hair-growth programs, "anti-aging" packages, microneedling, PRP, or mesotherapy-style skin injections. Those pairings are evidence of market behavior, not proof of controlled combination efficacy. [Copper peptide GHK-Cu encyclopedic record, 2026; GHK-Cu French encyclopedic record, 2026; Marie Claire, 2026]

Regulatory status

No FDA-approved human GHK-Cu injectable product, DailyMed label, or publicly indexed Drugs@FDA approval record was identified. Current 2026 reporting instead treats GHK-Cu as part of the unapproved peptide problem-space, where consumer demand, compounding pressure, and gray-market access outrun formal evidence. [Allure, 2026; Marie Claire, 2026]

Two regulatory principles matter even more than any peptide-specific meeting rumor. First, compounded drugs are not FDA-approved. Second, injectable peptide access through compounding or online sales does not itself validate safety, efficacy, or route equivalence. Reuters' 2026 reporting on compounded GLP-1 policy reiterated the FDA position that compounded drugs do not go through FDA approval and remain subject to federal limits. That principle applies here even though GHK-Cu is not a GLP-1. [Reuters, 2026]

A separate but important distinction is copper-therapeutic confusion. In January 2026, the FDA approved subcutaneous copper histidinate for Menkes disease. That approval does not help validate GHK-Cu. It proves that a copper complex can become a regulated injectable when it has clinical data, GMP manufacturing, and a defined indication. It does not imply that another copper complex inherits the same status or risk profile. [Reuters, 2026; Copper histidinate record, 2026]

Purported benefits, by evidence

Key literature

Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature. 1973. Early recognition of the biologic relevance of the tripeptide system.

Growth-modulating serum tripeptide is glycylhistidyllysine. Experientia. 1977. Molecular identification of GHK.

Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980. Early copper transport/copper uptake logic.

The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochemical Journal. 1981. Copper-binding architecture and stability relevance.

The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. 2003. Local wound-healing plausibility in a veterinary model.

Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology. 2006. Additional local wound-model support.

A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences. 2007. Matrix-based local wound-delivery concept.

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. Broad integrative summary of GHK-Cu biology.

Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2024. Current topical framing and formulation concerns.

References

• Marie Claire. "Meet GHK-Cu, the Copper Peptide Taking Over Your Skincare Feed—Here's Whether It's Worth the Hype." 2026.
• Allure. "The FDA May Reverse a Ban on Several Peptides With Potential Beauty Benefits. What Does That Mean, Exactly?" 2026.
• Reuters. "US FDA clarifies policies on compounding of GLP-1 medicines." 2026.
• Reuters. "US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease." 2026.
• New York Post. "Welcome to the 'peptide gray market': where people are buying GLP-1s, Botox and filler on social media from China." 2026.
• Business Insider. "Superpower wants to make you hotter, smarter, and healthier." 2026.

‍